𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrant p53 expression

✍ Scribed by Miguel Aguilar-Santelises; Kristinn P. Magnusson; Klas G. Wiman; Håkan Mellstedt; Mikael Jondal

Publisher
John Wiley and Sons
Year
1994
Tongue
French
Weight
632 KB
Volume
58
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We have analysed the p53 status in non‐progressive and progressive chronic B‐cell leukaemia (B‐CLL) by ELISA, immunoprecipitation, FACS and cDNA sequencing in relation to in vitro proliferation in response to Staphylococcus aureus strain Cowan I (SAC) and IL‐2. In FACS, cells from progressive leukaemia were found to over‐express p53 with a conformation recognized by PAb240. In a PAb240‐based ELISA, 60% of progressive B‐CLL were positive. DNA sequencing of p53 exons 5 to 9 revealed a codon 179 His to Gln change in one of the ELISA‐positive, progressive B‐CLL but failed to reveal any mutations in 4 other ELISA‐positive, progressive B‐CLL Among progressive B‐CLL populations, 10/14 responded by proliferation in vitro to SAC/IL‐2. In non‐progressive cells, low levels of p53 were found by FACS, none was positive in the PAb240 ELISA and only one case showed a weak proliferative response to SAC/IL‐2. Low p53 expression was also seen in different types of normal B cells, resting and activated, and in EBV‐transformed B‐cell lines, in contrast to the high expression observed in Burkitt lymphoma cell lines with verified p53 mutations. We conclude that progressive B‐CLL is characterized by aberrant p53 expression which may be a significant prognostic factor.

📜 SIMILAR VOLUMES

T-cell CD38 expression in B-chronic lymp
T-cell CD38 expression in B-chronic lymphocytic leukaemia
✍ Nashwa Khayrat Abousamra; Manal Salah EL-Din; Emad Azmy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

## Abstract B‐cell chronic lymphocytic leukaemia (B‐CLL) is a heterogeneous disease with some patients having an indolent course never needs treatment, while others having rapidly progressive one requires intensive treatment. In recent decades, numerous prognostic markers, such as immunoglobulin va

Selective inhibition of PED protein expr
Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis
✍ Michela Garofalo; Giulia Romano; Cristina Quintavalle; Maria Fiammetta Romano; F 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 489 KB

## Abstract B‐cell chronic lymphocytic leukaemia (B‐CLL) cells fail to undergo apoptosis. The mechanism underlying this resistance to cell death is still largely unknown. Tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) effectively kills tumour cells but not normal cells, and thus r

CD38 as a prognostic factor in B cell ch
CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): Comparison of three approaches to analyze its expression
✍ Joke G. Boonstra; Kirsten van Lom; Anton W. Langerak; Wilfried J. Graveland; Pet 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 411 KB 👁 1 views

## Abstract ## Background: Increased CD38 expression by leukemic cells has been suggested as an adverse prognostic factor in B‐CLL. Several approaches have been proposed to quantify its level of expression by flow cytometry. ## Methods: We compared the use of (i) the percentage of CD38 positive